Clinical Trials · NCT04113005
Safety and Tolerability Analysis of Combining Desmopressin With Docetaxel for the Treatment of Castration-Resistant Prostate Cancer
- Phase
- EARLY_Phase 1
- Recruitment status
- Unknown
- Sponsor
- Sunnybrook Health Sciences Centre
- Enrollment
- 10
- Start date
- Oct 2019
- Locations
- See registry
- Primary endpoint
- Number of subjects presenting with AEs within a 21-day period of time post Desmopressin/Docetaxel treatment; nature and severity of AEs (as per Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, Appendix B).